Alain Taylon
Endocrinology, Diabetes & Metabolism · Omaha, NENPI 1710023866
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 411 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Novo Nordisk at 34.7% of the total. Reporting peaked in 2019 at $2,055 and has fallen 93.0% since, to $143 in 2023.
Across 411 payments — averaging $10.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$660
- Sanofi-aventis U.S. LLC$442
- Amgen$279
- Abbott$216
- AstraZeneca$216
- plus $1K from 24 others
Across 2 payments — averaging $1375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$3K
What the payments were for
- Food & beverage$4,37798%
- Education$140%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 211 | $1,546 |
| Lilly USA, LLC | 50 | $660 |
| Sanofi-aventis U.S. LLC | 32 | $442 |
| Amgen(2 entities) | 17 | $279 |
| Abbott | 13 | $216 |
| AstraZeneca | 12 | $216 |
| Dexcom, Inc. | 10 | $158 |
| Insulet Corporation | 9 | $145 |
| Valeritas, Inc. | 17 | $133 |
| Mannkind Corporation | 6 | $131 |
| Amarin Pharma, Inc. | 4 | $67 |
| Boehringer Ingelheim | 5 | $62 |
| AbbVie | 4 | $54 |
| Zealand Pharma US, Inc. | 3 | $48 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Senseonics, Incorporated | 1 | $19 |
| Medtronic | 1 | $19 |
| EUSA Pharma (US) LLC | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Bayer | 1 | $16 |
| IBSA Pharma Inc. | 1 | $14 |
| Companion Medical, Inc. | 1 | $14 |
| Corcept Therapeutics | 1 | $14 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
How this compares
$4,451 in reported general payments places this provider in the 70th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $1,116 |
| Rosuvastatin Calcium | 15 | $534 |
| Levothyroxine Sodium | 23 | $237 |
| Glimepiride | 22 | $175 |
| Atorvastatin Calcium | 11 | $174 |
| Metformin Hcl | 26 | $144 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Omaha
- Marium IlahiOmaha$170K
- Cyrus DesouzaOmaha$86K
- Timothy WahlOmaha$41K
- Leslie EilandOmaha$17K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
- Andjela DrincicOmaha$14K
- Laura Graeff-ArmasOmaha$11K
- Claire BakerOmaha$6K
- Mohsen ZenaOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.